Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Multi-center Randomized Open Label Phase II Trial on Three Rituximab Dosing Schemes in Immune Thrombocytopenia Patients

Jaap J. Zwaginga,Bronno van der Holt,Peter A. te Boekhorst,Bart J. Biemond,Mark-David Levin,Rene van der Griend,Anneke Brand,Sonja Zweegman,Hans F. M. Pruijt,Vera M. J. Novotny,Art Vreugdenhil,Marco R. de Groot,Okke de Weerdt,Elisabeth C. M. van Pampus, Tanja M. van Maanen-Lamme,Shulamiet Wittebol,Martin R. Schipperus,Matthijs H. Silbermann,Peter C. Huijgens,Marleen Luten,Rene Hollestein,Jan A. C. Brakenhoff, Jolanda G. Schrama,Fransje A. A. Valster,Gerjo A. Velders,Harry R. Koene

Haematologica（2015）

Cited 19|Views45
Key words
immune thrombocytopenia,rituximab,splenectomy delaying,early response,open label phase II
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined